Collaboration
Nuevolution A/S has entered into a lead discovery collaboration focused on epigenetic disorders, setting up a consortium with two other companies, EpiTherapeutics, and ExpreS2ion Biotechnologies and the research group of Kristian Helin at the Biotech Research & Innovation Centre at the University of Copenhagen.
The DKK 24 million (€3.1 million) project is supported by the Danish High Technology Fund.
Nuevolution will apply its proprietary Chemetics technology to screen hundreds of millions small molecules against epigenetic targets.
“We believe that this consortium of skills represents the ideal combination to efficiently identify and develop novel drug leads [against] epigenetic-based disorders,” said Alex Gouliaev, CEO of Nuevolution.
Receive our Policy Bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
